Canady Helios Cold Plasma Scalpel Successfully Used by Chaim Sheba Medical Center Surgeons to Remove Inoperable Retroperitoneal Cancer

TAKOMA PARK, Md.–(BUSINESS WIRE)–#510K–A surgical team at The Chaim Sheba Medical Center in Tel HaShomer, Israel, with coordination by US Medical Innovations, LLC (USMI), successfully used the Canady Helios^TM Cold Plasma Scalpel (CHCPS) for a rare advanced reoccurring inoperable retroperitoneal sarcoma.

CHCPS is new cold atmospheric plasma device that specifically eradicates microscopic remnants of cancer cells while sparing normal cells and tissue.

After a one-time pre-market Humanitarian Compassionate-Use Exemption from the Investigational Review Board at Sheba Medical Center, a surgical team successfully used the Canady Helios^TM Cold Plasma Scalpel (CHCPS) for the selective killing of cancerous tissue during the groundbreaking surgery. The surgery was performed on August 20, 2019 on a 33-year-old man with a rare inoperable Retroperitoneal Sarcoma. The patient was first diagnosed at age 20 and the tumor had reoccurred twice prior to this surgery.

Retroperitoneal sarcoma occurs in the retroperitoneum, the area behind the peritoneum. The peritoneum is a thin tissue lining of the abdominal area that covers the abdominal organs. The surgery entailed removing the tumor and its attachment to adjacent tissue in the abdomen. Afterwards, the patient received intra-operative radiation therapy (IORT) at the surgical resected site; cold plasma was subsequently sprayed over the surgical site. The surgery was successful, and the patient returned back to the U.S. in September 2019.

A multidisciplinary group of healthcare professionals and physicians from Sheba Medical Center and research scientists, and engineers from USMI collaborated to achieve this successful outcome. The complex surgery was performed by Aviram Nissum, M.D. Chief of General and Oncological surgery at Sheba Medical Center.

USMI CEO, Chief Science Officer and Surgeon, Jerome Canady, M.D., “USMI and its sister companies are quite excited about the excellent outcome for the patient.” We are equally enthusiastic that CHCPS is approved by the FDA for a multi-center phase I clinical trial Investigational Device Exemption (IDE #G190195). Clinical trials will occur at Sheba Medical Center, Tel HaShomer, Israel and Rush University Medical Center, Chicago, Illinois starting February 2020.

About US Medical Innovations, LLC

US Medical Innovations, LLC (USMI) is a private U.S. biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC. USMI’s focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.

Contacts

US Medical Innovations, LLC

Kenniah Chestnut, Esq. VP Corporate Affairs

301-270-0147

[email protected]
www.usmedinnovations.com